Topographic EEG studies of mania

Area of Science:

• Neuroscience
• Psychiatry
• Quantitative Electroencephalography (qEEG)

Background:

• Manic patients exhibit distinct electrophysiological patterns.
• Pharmacotherapy, including lithium and carbamazepine, is a primary treatment for mania.
• Understanding qEEG changes during treatment is crucial for optimizing patient outcomes.

Purpose of the Study:

• To investigate quantitative electroencephalography (qEEG) findings in hospitalized manic patients.
• To compare qEEG profiles during drug-free periods and after various pharmacotherapies.
• To identify baseline qEEG predictors of treatment response and correlate qEEG with manic symptoms.

Main Methods:

• Collected qEEG data from 39 hospitalized manic patients.
• Analyzed qEEG during drug-free states and after monotherapy (lithium, carbamazepine) or combination therapy (lithium with carbamazepine, haloperidol, or risperidone).
• Compared a subsample of drug-free patients with normal controls and analyzed correlations between qEEG parameters, plasma drug levels, and manic symptom ratings.

Main Results:

• Drug-free manic patients showed lower qEEG amplitudes in left anterior and midtemporal regions compared to controls.
• Lithium therapy increased delta amplitudes and total power; lithium-containing regimens increased fast frequencies compared to carbamazepine alone.
• Non-responders exhibited increased generalized theta amplitudes at baseline and higher left temporal amplitudes post-treatment; psychopathology levels negatively correlated with qEEG amplitudes.

Conclusions:

• qEEG findings suggest dominant temporal lobe dysfunctions in mania.
• Different pharmacotherapies induce distinct qEEG changes, offering insights into treatment mechanisms.
• Baseline qEEG may predict treatment response, highlighting the potential of qEEG as a biomarker in bipolar disorder management.